Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.
Shintaro Kanda
Honoraria - Sanofi
Yuichiro Ohe
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Hidehito Horinouchi
No relevant relationships to disclose
Yutaka Fujiwara
No relevant relationships to disclose
Hiroshi Nokihara
No relevant relationships to disclose
Noboru Yamamoto
No relevant relationships to disclose
Ikuo Sekine
No relevant relationships to disclose
Hideo Kunitoh
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Kaoru Kubota
Honoraria - AstraZeneca
Tomohide Tamura
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi